Skip to content
DataLookout
Menu

PROLIFENCT05345587

Quality of Life and Economic Repercussions of Combining Proactive Medication Assessment and Electronic Monitoring of Toxicities in Subjects Undergoing Oral Cancer Therapy

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion date changed from estimate of Oct 2025 to Oct 7, 2026 Show 5 more changesShow less
    • Eligibility criteria expanded, about 15 words
    • Trial status changed: Unknown → Completed
    • Final enrollment: 152 participants (planned 196)
    • Secondary endpoints: details revised at 12 of 35 entries
    • Site details revised at 6 of 6 sites
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Notable Primary completion date: Oct 2024 to Oct 2025
    • Study sites: 4 to 6
    • Study completion date: Oct 2025 to Oct 2026
    v5
  4. Notable Primary completion date: Oct 2023 to Oct 2024
    • Study completion date: Oct 2023 to Oct 2025
    v4
  5. Notable Enrollment target: 300 to 196
    • Eligibility criteria expanded, about 6 words
    • Study sites: 3 to 4
    • Secondary endpoints: 42 to 35
    v3
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2022 to Sep 16, 2022
    • Site details revised at 3 of 3 sites
    v2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time until decrease in quality of life by 5-points between groups
Timeframe: End of follow-up maximum 18 months

Secondary (10)

Time until progression of cancer between groups
Patient satisfaction with their treatment between groups
Quality of life adjusted years between groups
Cost of care between groups
Toxicity experienced during treatment between groups
Show 5 moreShow less
Relative Dose Intensity between groups
Budget Impact Analysis
Rate of prescription changes since initiation of oral therapy (whether change in usual treatment and oral therapy).
Medication observance
Usability of the Thess monitoring patient interface for the collection of Patient Reported Outcomes

Arms and interventions

Prolife groupExperimental

scheduled consultation with the hospital clinical pharmacist, therapeutic follow-up and collection of clinical information by the patient via the THESS monitoring system

Standard careNo intervention

Other: THESS monitoring

Sites

6 sites in 1 country